Interactive Roundtable: How do you use ctDNA to Inform Clinical Trial Decision Making

Time: 2:30 pm


• Alongside peers considering shifting pipelines to adjuvant settings, discuss challenges and clinical considerations to ensure we’re intervening via liquid biopsy-based means in the right way
• Address concerns over data (& lack thereof!) in the non-metastatic space to determine the utility of ctDNA monitoring in future trial design and decision making
• Answer what could the successful implementation of ctDNA monitoring in trial decision look like and how is this streamlining stratification with the avoidance of patients receiving unnecessary treatments?